Lumos Pharma Announces New Data And Analysis Of 15 Subjects From OraGrowtH212 Trial Presented At The 2023 ESPE Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Lumos Pharma, Inc. (NASDAQ:LUMO) presented new data and analysis from its OraGrowtH212 Trial at the 2023 ESPE Annual Meeting. The analysis shows a 60% increase in GH secretion and a 62% increase in annualized height velocity compared to baseline. The data supports the mechanism of action for LUM-201, Lumos' oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), currently in Phase 2 clinical trials. The company expects topline data from these trials in the fourth quarter.
September 26, 2023 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lumos Pharma's new data from its OraGrowtH212 Trial supports the potential of LUM-201 as a treatment for moderate PGHD. This positive news could boost investor confidence and potentially impact the company's stock price positively in the short term.
The new data presented by Lumos Pharma shows promising results for their oral therapeutic candidate, LUM-201. This could increase investor confidence in the company's ability to successfully bring this product to market, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100